Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHGCY Chugai Pharmaceutical	$23.23 -0.5%	$25.35	$18.40 ▼ $31.26	$76.32B	0.66	314,415 shs	1.13 million shs
TAK Takeda Pharmaceutical	$14.42 -2.2%	$14.83	$12.80 ▼ $15.53	$45.92B	0.23	2.02 million shs	3.64 million shs
UCBJY UCB	$101.30 +0.4%	$93.90	$71.16 ▼ $106.60	N/A	0.51	33,024 shs	16,018 shs
ZTS Zoetis	$148.61 -0.9%	$160.77	$139.70 ▼ $200.33	$66.16B	0.91	2.62 million shs	4.72 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHGCY Chugai Pharmaceutical	0.00%	-0.17%	-7.34%	-19.56%	+21.24%
TAK Takeda Pharmaceutical	0.00%	-1.70%	-3.25%	-1.80%	+5.26%
UCBJY UCB	0.00%	+1.04%	+13.35%	+30.04%	+30.90%
ZTS Zoetis	0.00%	-4.07%	-4.25%	-0.02%	-18.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHGCY Chugai Pharmaceutical	1.3187 of 5 stars	0.0	3.0	2.5	0.0	2.8	0.0	0.6
TAK Takeda Pharmaceutical	2.3129 of 5 stars	0.0	5.0	2.5	0.0	3.4	0.0	0.6
UCBJY UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	4.9571 of 5 stars	4.4	5.0	4.2	0.4	2.9	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHGCY Chugai Pharmaceutical	0.00	N/A	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
UCBJY UCB	4.00	Strong Buy	N/A	N/A
ZTS Zoetis	2.70	Moderate Buy	$204.63	37.69% Upside

Current Analyst Ratings Breakdown

Latest UCBJY, CHGCY, ZTS, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	ZTS Zoetis	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $155.00
7/16/2025	UCBJY UCB	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHGCY Chugai Pharmaceutical	$7.74B	9.87	$0.84 per share	27.54	$3.81 per share	6.10
TAK Takeda Pharmaceutical	$30.09B	1.53	$3.18 per share	4.54	$14.39 per share	1.00
UCBJY UCB	$6.66B	N/A	$3.95 per share	25.63	N/A	N/A
ZTS Zoetis	$9.26B	7.15	$7.07 per share	21.02	$10.57 per share	14.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHGCY Chugai Pharmaceutical	$2.56B	$0.81	28.68	29.78	N/A	33.56%	21.71%	18.98%	7/24/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	65.55	8.74	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
UCBJY UCB	$1.15B	N/A	0.00	23.56	0.67	N/A	N/A	N/A	7/23/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	26.68	22.02	2.46	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest UCBJY, CHGCY, ZTS, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ZTS Zoetis	$1.61	N/A	N/A	N/A	$2.41 billion	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/24/2025	Q1 2025	CHGCY Chugai Pharmaceutical	N/A	$0.19	N/A	$0.19	N/A	$1.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHGCY Chugai Pharmaceutical	$0.26	1.12%	N/A	32.10%	N/A
TAK Takeda Pharmaceutical	$0.55	3.81%	N/A	250.00%	N/A
UCBJY UCB	$0.48	0.47%	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.35%	N/A	35.91%	14 Years

Latest UCBJY, CHGCY, ZTS, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
4/21/2025	UCBJY UCB		$0.4838	0.62%	4/28/2025	4/29/2025	5/14/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHGCY Chugai Pharmaceutical	N/A	7.28	6.16
TAK Takeda Pharmaceutical	0.57	1.01	0.52
UCBJY UCB	0.30	1.36	0.99
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHGCY Chugai Pharmaceutical	0.01%
TAK Takeda Pharmaceutical	9.17%
UCBJY UCB	N/A
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CHGCY Chugai Pharmaceutical	N/A
TAK Takeda Pharmaceutical	0.04%
UCBJY UCB	N/A
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHGCY Chugai Pharmaceutical	7,778	3.29 billion	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
UCBJY UCB	9,378	N/A	N/A	Not Optionable
ZTS Zoetis	13,800	445.21 million	444.41 million	Optionable

UCBJY, CHGCY, ZTS, and TAK Headlines

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Heritage Investors Management Corp

July 20 at 8:20 AM | marketbeat.com

AustralianSuper Pty Ltd Has $14.24 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 20 at 6:39 AM | marketbeat.com

Leerink Partnrs Weighs in on Zoetis' Q3 Earnings (NYSE:ZTS)

July 20 at 2:04 AM | americanbankingnews.com

Kestra Private Wealth Services LLC Trims Holdings in Zoetis Inc. (NYSE:ZTS)

July 19 at 10:31 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Carnegie Lake Advisors LLC

July 19 at 9:11 AM | marketbeat.com

Leerink Partners Downgrades Zoetis (NYSE:ZTS) to Market Perform

July 19 at 2:47 AM | americanbankingnews.com

Is Zoetis (ZTS) a Unique Dividend Play in the Pharma Space for 2025?

July 18 at 10:28 PM | insidermonkey.com

Argus Trims Zoetis (ZTS) Price Target to $190, Keeps Constructive View

July 18 at 3:21 PM | insidermonkey.com

Why Zoetis (ZTS) Could Beat Earnings Estimates Again

July 18 at 1:11 PM | zacks.com

Zoetis (NYSE:ZTS) Lowered to Hold Rating by Leerink Partnrs

July 18 at 12:03 PM | marketbeat.com

Diversify Advisory Services LLC Has $2.53 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 18 at 11:10 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Pictet Asset Management Holding SA

July 18 at 10:40 AM | marketbeat.com

Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)

July 18 at 9:59 AM | seekingalpha.com

Analysts Issue Forecasts for Zoetis' Q3 Earnings (NYSE:ZTS)

July 18 at 9:35 AM | marketbeat.com

Verdence Capital Advisors LLC Purchases 3,786 Shares of Zoetis Inc. (NYSE:ZTS)

July 18 at 7:20 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Segall Bryant & Hamill LLC

July 18 at 6:38 AM | marketbeat.com

Wealthfront Advisers LLC Grows Position in Zoetis Inc. (NYSE:ZTS)

July 18 at 5:57 AM | marketbeat.com

Cwm LLC Purchases 4,282 Shares of Zoetis Inc. (NYSE:ZTS)

July 18 at 4:48 AM | marketbeat.com

Leerink upgrades Elanco on pet health momentum, downgrades Zoetis

July 17 at 2:39 PM | investing.com

Here's Why Zoetis (ZTS) is a Strong Growth Stock

July 17 at 10:46 AM | zacks.com

Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls

July 17 at 10:44 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Super Micro Stock May Benefit as Cooling Demand Takes Off
By Gabriel Osorio-Mazilli | July 16, 2025
View Super Micro Stock May Benefit as Cooling Demand Takes Off

UCBJY, CHGCY, ZTS, and TAK Company Descriptions

Chugai Pharmaceutical OTCMKTS:CHGCY

$23.23 -0.12 (-0.51%)

As of 07/18/2025 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Takeda Pharmaceutical NYSE:TAK

$14.42 -0.32 (-2.17%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$14.42 +0.01 (+0.03%)

As of 07/18/2025 04:53 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB OTCMKTS:UCBJY

$101.30 +0.39 (+0.39%)

As of 07/18/2025 03:58 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Zoetis NYSE:ZTS

$148.61 -1.42 (-0.95%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$148.57 -0.04 (-0.03%)

As of 07/18/2025 07:59 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time